Jw Cayman Therapeutics Ltd.

Chinese cell‑therapy firm advancing multiple CAR‑T candidates—including relmacabtagene autoleucel for relapsed B‑cell lymphoma—and a broad pipeline targeting myeloma, solid tumours and auto‑immune disease, positioning it for growth in the expanding oncology market.

Headquarters: China (CHN)

Jw Cayman Therapeutics Ltd. Logo
Company Profile
  • Employees: 292
  • HQ: Shanghai
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
2126 Jw Cayman Therapeutics Ltd.
Cap: 1.0B
EQUITY HKG HKD KYG5210T1040 Active
📈
Home Login